| Literature DB >> 26604429 |
Nathalie Deckx1, Inez Wens2, Amber H Nuyts1, Wai-Ping Lee1, Niel Hens3, Gudrun Koppen4, Herman Goossens5, Pierre Van Damme6, Zwi N Berneman1, Bert O Eijnde2, Nathalie Cools1.
Abstract
In healthy individuals, one exercise bout induces a substantial increase in the number of circulating leukocytes, while their function is transiently suppressed. The effect of one exercise bout in multiple sclerosis (MS) is less studied. Since recent evidence suggests a role of dendritic cells (DC) in the pathogenesis of MS, we investigated the effect of one combined endurance/resistance exercise bout on the number and function of DC in MS patients and healthy controls. Our results show a rapid increase in the number of DC in response to physical exercise in both MS patients and controls. Further investigation revealed that in particular DC expressing the migratory molecules CCR5 and CD62L were increased upon acute physical activity. This may be mediated by Flt3L- and MMP-9-dependent mobilization of DC, as demonstrated by increased circulating levels of Flt3L and MMP-9 following one exercise bout. Circulating DC display reduced TLR responsiveness after acute exercise, as evidenced by a less pronounced upregulation of activation markers, HLA-DR and CD86, on plasmacytoid DC and conventional DC, respectively. Our results indicate mobilization of DC, which may be less prone to drive inflammatory processes, following exercise. This may present a negative feedback mechanism for exercise-induced tissue damage and inflammation.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26604429 PMCID: PMC4641936 DOI: 10.1155/2015/158956
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Clinical details of the study population.
| Controls | MS |
| |
|---|---|---|---|
| Gender (M/F) | 4/5 | 10/12 | 0.960 |
| Age ± SEM | 46 ± 3 | 46 ± 2 | 0.960 |
| BMI ± SEM | 25 ± 1 | 24 ± 1 | 0.424 |
| EDSS ± SEM | NA | 3 ± 0.2 | NA |
| Type MS (CP/RR) | NA | 9/12 | NA |
| Medication (untreated/1st-line treatment/2nd-line treatment) | NA | 4/12/6 | NA |
Patients were defined as untreated when a wash-out period of at least 3 months was respected before recruitment in the study. 1st-line treatment: IFN-β (Avonex, Betaferon, and Rebif) and glatiramer acetate (Copaxone); 2nd-line treatment: alemtuzumab (Campath), natalizumab (Tysabri), and fingolimod (Gilenya). Results are shown as mean ± SEM. Missing data from one patient.
Abbreviations used are as follows: MS: multiple sclerosis; M: male; F: female; BMI: body mass index; EDSS: expanded disability status scale; CP: chronically progressive MS; RR: relapsing-remitting MS; SEM: standard error of the mean; NA: not applicable.
Figure 1Leukocyte counts are increased upon physical exercise. Enumeration of the absolute number of immune cells was done by means of a double platform method using an automated cell counter and flow cytometry in healthy controls (green dots) and MS patients (red dots). Results are shown as mean absolute number ± SEM. Significance ( P < 0.05) in the complete population of both patients and controls is annotated by black lines, while green and red lines annotate significance in controls and patients, respectively. Abbreviations used are as follows: MS: multiple sclerosis; cDC: conventional dendritic cells; pDC: plasmacytoid dendritic cells; Treg: regulatory T-cell; FoxP3: forkhead box P3; IL: interleukin; Tr1: type 1 regulatory T-cell; TGF: transforming growth factor; Th3: T helper type 3 cell; before: measurement before the exercise test; after: measurement immediately after the test; 2 h: measurement 2 hours after the test; and SEM: standard error of the mean.
Figure 2Increased numbers of cDC and pDC expressing the migratory molecules, CD62L and CCR5, upon one exercise bout. The migratory profile of DC was assessed by enumerating cDC and pDC expressing CD62L and CCR5 in healthy controls (green dots) and MS patients (red dots). Results are shown as mean absolute number ± SEM. Significance ( P < 0.05) in the complete population of both patients and controls is annotated by black lines. Abbreviations used are as follows: MS: multiple sclerosis; cDC: conventional dendritic cells; pDC: plasmacytoid dendritic cells; CD62L: CD62 ligand; CCR: C-C chemokine receptor; before: measurement before the exercise test; after: measurement immediately after the test; 2 h: measurement 2 hours after the test; and SEM: standard error of the mean.
Figure 3Induction of Flt3L and MMP-9 upon physical exercise. The serum level of Flt3L and MMP-9 was measured by means of ELISA in healthy controls (green dots) and MS patients (red dots). Results are shown as mean concentration ± SEM. Significance ( P < 0.05) in the complete population of both patients and controls is annotated by black lines, while green and red lines annotate significance in controls and patients, respectively. Abbreviations used are as follows: MS: multiple sclerosis; Flt3L: Fms-related tyrosine kinase 3 ligand; MMP: matrix metalloproteinase; before: measurement before the exercise test; after: measurement immediately after the test; 2 h: measurement 2 hours after the test; and SEM: standard error of the mean.
Figure 4Decreased activation state of DC upon TLR stimulation after one exercise bout in healthy controls (white bars) and MS patients (grey bars). MFI of CD86 and HLA-DR expression on cDC and pDC after LPS and IFN-γ or IQ stimulation, respectively, was measured using flow cytometry. Mean fold changes are calculated as the ratio between the MFI in the stimulated condition and the nonstimulated condition. Then, % changes after exercise and after 2 hours of rest with respect to the baseline value are calculated. Results are shown as mean % change ± SEM. P < 0.05 for the difference between results before and after the test. # indicates a significant effect between before and 2 hours after the test. § indicates a significant effect between after and 2 hours after the test. Abbreviations used are as follows: cDC: conventional dendritic cells; pDC: plasmacytoid dendritic cells; LPS: lipopolysaccharide; IFN: interferon; IQ: imiquimod; HLA: human leukocyte antigen; MFI: mean fluorescence intensity; after: measurement immediately after the test; 2 h: measurement 2 hours after the test; and SEM: standard error of the mean.
Figure 5Increased secretion of inflammatory mediators upon TLR stimulation after one exercise bout. Blood samples of healthy controls (white bars) and MS patients (grey bars) were (i) stimulated overnight with LPS in combination with IFN-γ or (ii) left unstimulated. Secretion of inflammatory mediators was quantified using ELISA. For the secretion of TNF-alpha, only patients on 2nd-line treatment are depicted. Mean fold changes are calculated as the ratio of the secreted concentration in the stimulated condition to the nonstimulated condition. Then, % changes after exercise and after 2 hours of rest with respect to the baseline value are calculated. Results are shown as mean % change ± SEM. P < 0.05 for the difference between results before and after the test. # indicates a significant effect between before and 2 hours after the test. § indicates a significant effect between after and 2 hours after the test. Abbreviations used are as follows: LPS: lipopolysaccharide; IL: interleukin; TNF: tumour necrosis factor; IFN: interferon; MMP: matrix metalloproteinase; after: measurement immediately after the test; 2 h: measurement 2 hours after the test; and SEM: standard error of the mean.